Join Drs Benjamin Schlechter and Cathy Eng as they discuss the treatments and clinical trials available for patients with refractory colorectal cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000091. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/25970050/ Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/37133585/ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/23177514/ Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Asian Patients With Previously Treated Metastatic Colorectal Cancer (CONCUR): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/25981818/ Regorafenib Dose-Optimisation in Patients With Refractory Metastatic Colorectal Cancer (ReDOS): A Randomised, Multicentre, Open-Label, Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/31262657/ Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial https://pubmed.ncbi.nlm.nih.gov/33604969/ Fruquintinib Versus Placebo in Patients With Refractory Metastatic Colorectal Cancer (FRESCO-2): An International, Multicentre, Randomised, Double-Blind, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/37331369/ Targeting KRAS in Cancer https://pubmed.ncbi.nlm.nih.gov/38637634/ Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/29946728/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related